Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MiSTIC: CHF 5993 vs CHF 1535 in Uncontrolled Asthma
NCT05018598Phase 4Terminated
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Feb 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of glycopyrronium bromide in asthma, sponsored by Chiesi Farmaceutici S.p.A.. Started Feb 2022; status: terminated.
02
Drugs
glycopyrronium bromide
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05018598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05018598.